caa a22 4500 475833171 CHVBK 20180406123846.0 cr unu---uuuuu 170329e20000201xx s 000 0 eng 10.1023/A:1007843205311 doi (NATIONALLICENCE)springer-10.1023/A:1007843205311 Angiotensin II Formation in Human Vasculature after Chronic ACE Inhibition: A Prospective, Randomized, Placebo-Controlled Study [Elektronische Daten] [Margreeth Oosterga, Adriaan Voors, Hendrik Buikema, Yigal Pinto, Harry Haber, Tjark Ebels, Wim Morshuis, J. Kingma, Harry Crijns, Wiek van Gilst] The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on angiotensin II formation in human vasculature. Patients (n < 187) scheduled for coronary artery bypass surgery used study medication 27 ± 1 days before surgery. Segments of internal mammary arteries were exposed to increasing doses (0.1 nM-1 µM) of angiotensin I and II in organ baths. The rate of local angiotensin II formation is a function of the reciprocal of the difference between the pEC50's of the dose response curves to angiotensin I and II (−log/mol) and of the area between the curves (units). Quinapril (40 mg) and captopril (3×50 mg) similarly and significantly reduced mean blood pressure compared with placebo (p = 0.04). Difference between pEC50's was 0.90 ± 0.08 in quinapril patients compared with 0.60 ± 0.08 for placebo (p <5 0.01); the area between curves was 91 ± 8 for quinapril patients compared with 67 ± 8 for placebo (p = 0.03). Angiotensin II formation was decreased to a lesser extent with captopril and was not statistically different from placebo (p = 0.3); the difference between pEC50's was 0.83 ± 0.15; the area between curves was 84 ± 12. This is the first randomized study to demonstrate that long-term oral treatment with an ACE inhibitor reduces vascular angiotensin II formation in humans. Kluwer Academic Publishers, 2000 angiotensin nationallicence ACE inhibition nationallicence vasculature nationallicence endothelial factors nationallicence renin-angiotensin system nationallicence Oosterga Margreeth Department of Clinical Pharmacology, University of Groningen, The Netherlands aut Voors Adriaan Department of Clinical Pharmacology, University of Groningen, The Netherlands aut Buikema Hendrik Department of Clinical Pharmacology, University of Groningen, The Netherlands aut Pinto Yigal Department of Clinical Pharmacology, University of Groningen, The Netherlands aut Haber Harry Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan, USA aut Ebels Tjark Department of Thoracic Surgery, University Hospital Groningen, The Netherlands aut Morshuis Wim Department of Thoracic Surgery, St Antonius Hospital Nieuwegein, The Netherlands aut Kingma J. Department of Cardiology, St. Antonius Hospital Nieuwegein, The Netherlands aut Crijns Harry Department of Cardiology, University Hospital Groningen, The Netherlands aut van Gilst Wiek Department of Clinical Pharmacology, University of Groningen, The Netherlands aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 55-60 0920-3206 14:1<55 2000 14 10557 https://doi.org/10.1023/A:1007843205311 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007843205311 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Oosterga Margreeth Department of Clinical Pharmacology, University of Groningen, The Netherlands aut NATIONALLICENCE 700 1- Voors Adriaan Department of Clinical Pharmacology, University of Groningen, The Netherlands aut NATIONALLICENCE 700 1- Buikema Hendrik Department of Clinical Pharmacology, University of Groningen, The Netherlands aut NATIONALLICENCE 700 1- Pinto Yigal Department of Clinical Pharmacology, University of Groningen, The Netherlands aut NATIONALLICENCE 700 1- Haber Harry Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan, USA aut NATIONALLICENCE 700 1- Ebels Tjark Department of Thoracic Surgery, University Hospital Groningen, The Netherlands aut NATIONALLICENCE 700 1- Morshuis Wim Department of Thoracic Surgery, St Antonius Hospital Nieuwegein, The Netherlands aut NATIONALLICENCE 700 1- Kingma J. Department of Cardiology, St. Antonius Hospital Nieuwegein, The Netherlands aut NATIONALLICENCE 700 1- Crijns Harry Department of Cardiology, University Hospital Groningen, The Netherlands aut NATIONALLICENCE 700 1- van Gilst Wiek Department of Clinical Pharmacology, University of Groningen, The Netherlands aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 55-60 0920-3206 14:1<55 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer